Olga MartÃ-nez-Sáez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1766238/publications.pdf

Version: 2024-02-01

1163117 1125743 14 582 8 13 citations g-index h-index papers 14 14 14 743 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Research, 2020, 22, 45.	5.0	175
2	Current and Future Management of HER2-Positive Metastatic Breast Cancer. JCO Oncology Practice, 2021, 17, 594-604.	2.9	102
3	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2020, 84, 101965.	7.7	92
4	Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. Journal of Clinical Oncology, 2021, 39, 1458-1467.	1.6	73
5	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. Nature Communications, 2020, 11, 385.	12.8	67
6	Gene expression profiles of breast cancer metastasis according to organ site. Molecular Oncology, 2022, 16, 69-87.	4.6	24
7	SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. Frontiers in Oncology, 2021, 11, 638482.	2.8	16
8	Safety and Oncological Outcomes of Bevacizumab Therapy in Patients With Advanced Colorectal Cancer and Self-expandable Metal Stents. Clinical Colorectal Cancer, 2019, 18, e287-e293.	2.3	15
9	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. EBioMedicine, 2021, 69, 103451.	6.1	7
10	Primary Neuroendocrine Tumor of the Parotid Gland: A Case Report and a Comprehensive Review of a Rare Entity. Case Reports in Otolaryngology, 2016, 2016, 1-5.	0.2	5
11	Aquaporin-4-Positive Triple-Negative Breast Cancer Presenting with Paraneoplastic Neuromyelitis Optica Spectrum Disorder. Biomedicine Hub, 2022, 7, 11-16.	1.2	2
12	Abstract PD13-04: Activity of patritumab deruxtecan, a HER3-directed antibody drug conjugate, in early breast cancer according to ERBB3 expression: Interim analysis results of a window-of-opportunity study (SOLTI-1805 TOT-HER3). Cancer Research, 2022, 82, PD13-04-PD13-04.	0.9	2
13	Abstract P4-07-08: Prognostic value of intrinsic subtypes (IS) in hormone receptor-positive (HoR+) metastatic breast cancer (MBC): A systematic review and meta-analysis of prospective trials. Cancer Research, 2022, 82, P4-07-08-P4-07-08.	0.9	2
14	Abstract P4-11-28: Collecting quality of life information in a cohort of breast cancer survivors-Integrating electronic data collection into clinical practice. Cancer Research, 2022, 82, P4-11-28-P4-11-28.	0.9	0